贝伐珠单抗联合AP化疗方案治疗老年肺腺癌患者的效果  

Effects of Bevacizumab combined with AP chemotherapy in treatment of elderly patients with lung adenocarcinoma

作　　者：万闹 WAN Nao(Second Department of Oncology of Nanyang First People’s Hospital,Nanyang 473000 Henan,China)

机构地区：[1]南阳市第一人民医院肿瘤二科,河南南阳473000

出　　处：《中国民康医学》2025年第5期44-46,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察贝伐珠单抗联合AP化疗方案治疗老年肺腺癌患者的效果。方法:回顾性分析2022年8月至2023年8月该院收治的88例老年肺腺癌患者的临床资料,按照治疗方法不同将其分为观察组与对照组各44例。对照组采用AP化疗方案(培美曲塞+顺铂)治疗,观察组在对照组基础上联合贝伐珠单抗治疗。比较两组临床疗效,治疗前后肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)]水平、健康状态[Karnofsky功能状态量表(KPS)]评分,以及不良反应发生率。结果:观察组疾控控制率(DCR)为77.27%(34/44),高于对照组的52.27%(23/44),差异有统计学意义(P<0.05);治疗后,两组CEA、NSE、CYFRA21-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组KPS评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组肝肾功能异常、消化道不适、血小板减少、中性粒细胞减少等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:贝伐珠单抗联合AP化疗方案治疗老年肺腺癌患者可提高DCR和健康状态评分,降低肿瘤标志物水平,效果优于单纯AP化疗方案治疗。Objective:To observe effects of Bevacizumab combined with AP chemotherapy in treatment of elderly patients with lung adenocarcinoma.Methods:The clinical data of 88 elderly patients with lung adenocarcinoma admitted to this hospital from August 2022 to August 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,44 cases in each group.The control group was treated with AP chemotherapy(Pemetrexed+Cisplatin),while the observation group was treated with Bevacizumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers [carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)] and the health status scale [Karnofsky performance status(KPS)] score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate(DCR) of the observation group was 77.27%(34/44),which was higher than 52.27%(23/44) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA,NSE and CYFRA21-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,that in the observation group was higher than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as abnormal liver and kidney function,gastrointestinal discomfort,thrombocytopenia and neutropenia between the two groups(P>0.05).Conclusions:Bevacizumab combined with AP chemotherapy in the treatment of the elderly patients with lung adenocarcinoma can improve the DCR and the health status scores,and reduce the levels of tumor markers.Moreover,it is superior t

关 键 词：老年 肺腺癌 贝伐珠单抗 培美曲塞 顺铂 肿瘤标志物 健康状态 

分 类 号：R734.2[医药卫生—肿瘤]